


Thalassamia

Hemoglobin Types

Hemoglobin Type	Globin Chains
• Hgb A—92%-----	$\alpha_2\beta_2$
• Hgb A2—2.5%-----	$\alpha_2\delta_2$
• Hgb F — <1%-----	$\alpha_2\gamma_2$
• Hgb H -----	β_4
• Bart's Hgb-----	γ_4
• Hgb S-----	$\alpha_2\beta_2$ 6 ^{glu→val}
• Hgb C-----	$\alpha_2\beta_2$ 6 ^{glu→lys}




Other genetic variants of β thalassaemia

1-Haemoglobin Lepore

- unequal crossing over between the beta (β) gene and the delta (δ) gene.
- Crossing over produced a delta-beta fusion gene, which may well be functional, but is expressed at very low levels because it is controlled by the very weak delta gene promoter.
- This event gave rise to hemoglobin Lepore, which is a beta-thalassaemia
- It has the same E/P mobility as Hb S , **D.D:** by acid ph

- unequal crossing over
- hemoglobin Lepore (β -thalassaemia)



- unequal crossing over occurred due to the close homology of the δ - and β -genes: only 10 out of 146 residues differ (the genes are ~90% homologous to each other)
- the consequence can be severe β -thalassaemia due to decreased synthesis of the $\delta\beta$ -fusion (due to the weak δ -globin promoter)

Genetic variants & clinical presentation:

Homozygous:

$(\delta\beta)$ lepre/ $(\delta\beta)$ lepre

Hb A : 0

Hb A2: 0

Hb F : 70-92%

Hb lepre : 8-30%

Clinically :

Thalassamia major

Heterozygous:

$\beta/(\delta\beta)$ lepre

Hb A: 80-90 %

Hb A2: ↓

Hb F : 1-3%

Hb lepre : 5-15 %

Clinically :

Thalassamia minor

Double Heterozygous:

$\beta+ / (\delta\beta)$ lepre

$\beta_0 / (\delta\beta)$ lepre

Hb A: 0 in β_0 , present e' variable amount in $\beta+$

Hb A2: ↓

Hb F : ↑


Hb lepre : 10 %

Clinically :

Thalassamia intermedia

2- $\delta\beta$ Thalassamia

- ↓ or absent synthesis of δ and β globin chains .
- ↑ production of γ globin chain, but not enough to compensate for deficient δ and β globin production.
- So excess α chain deposit → more anaemia than HPFH



Genetic variants & clinical presentation:

Homozygous:

$(\delta\beta) o / (\delta\beta) o$

Hb A : 0

Hb A2: 0

Hb F : 100 %

Clinically :

Thalassamia intermedia

Heterozygous:

$\beta/(\delta\beta)_0$

Hb A: < 90 %

Hb A2: N or ↓

Hb F : ↑ 5-20 %

Clinically :

Thalassamia minor

3- Hereditary Persistence of foetal Hb (HPFH)

- ↓ or absent synthesis of δ and β globin chains .
- The ↑ production of γ globin chain, is sufficient to almost balance α chain synthesis .
- minimal α chain deposit → milder anaemia than $\delta\beta$ thalass.

Genetic variants & clinical presentation:

Homozygous:

HPFH/HPFH

Hb A : 0

Hb A2: 0

Hb F : 100 %

Clinically :

no anaemia

↓ MCV, ↓ MCH e' mild polycythemia

Heterozygous:

β / HPFH

Hb A: present

Hb A2: ↓

Hb F : 10-35 %

Clinically :

no clinical abnormality

Hb conc is N

MCV & MCH r slightly ↓

α Thalassaemia

deficient/absent α subunits

Molecular basis:

Mainly deletion

I- Deletion:

Of short arm of chromosome 16

II- Non deletion:

- Mutation of transcription
- „ „ processing
- „ „ translation

Deletion of both α genes on a chromosome = $\alpha\alpha$

„ „ 1 α gene „ „ „ = $\alpha+$

Defective fetal & adult Hb production

Hb A ($\alpha_2\beta_2$)

Hb A2 ($\alpha_2\delta_2$)

Hb F ($\alpha_2\gamma_2$)


In fetus: ↑ γ Hb Barts (γ_4)

In adults : | β Hb H (β_4)

Types:

- Silent Carrier
- Trait (Minor)
- Hemoglobin H Disease
- Major (Hemoglobin Bart's)

- normally there are four α -globin genes in heterozygotic somatic cells
- loss of α -globin genes results in different severities of α -thalassemia depending on the number of genes lost in combination with deletion chromosomes



Classification & Terminology of α Thalassemia

- Normal $\alpha\alpha/\alpha\alpha$
- Silent carrier $-\alpha/\alpha\alpha$
- Minor $-\alpha/-\alpha$
 $--/\alpha\alpha$
- Hb H disease $--/-\alpha$
- Barts hydrops fetalis $--/--$

α Thalassemia

- Result from gene deletions
- One deletion—Silent carrier; no clinical significance
- Two deletions—a Thal trait; mild hypochromic microcytic anemia
- Three deletions—Hgb H; variable severity, but less severe than Beta Thal Major
- Four deletions—Bart’s Hgb; Hydrops Fetalis; In Utero or early neonatal death

Clinical Outcomes of Alpha Thalassemia

- **Silent carriers**
 - asymptomatic
 - “normal”
- **Alpha Thalassemia minor (trait)**
 - no anemia
 - microcytosis
 - unusually small red blood cells due to fewer Hb in RBC
 - “normal”
- **Alpha Thalassemia intermedia (“Hemoglobin H”)**
 - microcytosis & hemolysis (breakdown of RBC)
 - results in severe anemia
 - bone deformities
 - splenomegaly (enlargement of spleen)
 - “severe and life threatening”
- **Alpha Thalassemia major**
 - Hb Bart’s
 - fatal hydrops fetalis
 - occurs in utero

Hydrops Foetalis

- No α chain at all (loss of 4 genes)
- Most severe form due to intra-uterine hypoxia, pallor, oedema, HSM
- Intra-uterine death (incompatible e' life)

Hb E/P:

Hb barts: (γ_4) ($\gamma_2 \gamma_2$)

Hb H : (β_4) ($\beta_2 \beta_2$)

Hb Portland: ($\zeta_2 \gamma_2$)

N.B: Hb H & Hb barts have high O₂ affinity.

D.D:

Rh incompatibility

	Rh incompatibility	Hydrops Foetalis
Rh of baby	+ ve	-ve or +ve
Direct Coomb's	Strong + ve	-ve
Hb electrophoresis	Normal	Abnormal Hb H or barts

Hb H disease

Deletion of 3 α genes $\alpha 0/\alpha+$ $--/-\alpha$

Hb H : $(\beta 4)$ $(\beta 2\beta 2)$

C/P:

- Chronic H.A
- Hb : 7-10 g/dl
- Hypochromia, target cs
- \uparrow Retics: 5-10 %
- Splenomegaly, hypersplenism
- Bony changes

Lab diagnosis:

Evidences

CBC:

- MHA
- Anisocytosis, poikilocytosis
- Retics 5-10%
- Hb H : brilliant cresyl blue \rightarrow inclusion bodies in all cells \rightarrow golf ball appearance
- **Hb E/P:**

On acid ph 6-7

- **At birth :**

Hb barts $(\gamma 4)$: 20-40 %

Hb F, A (the rest)


- **After 1 year:**

Hb H : 5-40 %

\pm Hb barts

Hb A : 25 %

Hb A2 : \downarrow



Acquired Hb H disease

- Observed in association e' pre-leukemic syndromes as MDS
- Occurs in elderly men

Lab:

RBCs r dimorphic : normal & hypochromic cells

Diagnosis:

Incubation on brilliant cresyl blue stain for 1 hour → Golf-ball appearance

Hb E/P:

Hb H 5-70 %

Clinical & Haematological features of α thalassaemia syndromes

Phenotype	Genotype	C/P	Newborn	After 1 year
Hydrops Foetalis	(- -/- -)	Neonatal death e' severe anaemia	Hb barts (γ 4) 80-90 %	Doesn't live
Hb H disease	(- -/- α)	Ch. H.A as thalas. intermedia	Hb barts 20-40 % Hb A,F	Hb H 5-30 % \pm Hb barts Hb A, A2
Thalass. minor	(- α /- α) (- -/ α α)	Little or no anaemia e' \downarrow MCV, MCH	Hb barts 2-10 %	Normal
Silent carrier	(- α / α α)	No clinical or haematological abnormalities	Hb barts 0-2%	Normal

Alpha Thalasseмииs

- Usually no treatment indicated
- 4 deletions incompatible with life
- 3 or fewer deletions have only mild anemia

Treatments for Alpha Thalasseमीa

- Silent Carrier – no treatment required
- Trait (Minor) – no treatment required
- Hemoglobin H Disease – Folate
 - avoid iron supplements
- Major (Hemoglobin Bart's) –RBC transfusion while still in doubt, else fetus is stillborn or dies shortly

Program for prevention of thalassaemia

I- Genetic counseling:

Screening all population at school age & warning carrier about the risk of marriage to another carrier

II- Pre-natal diagnosis & carrier detection:

A- Sampling:

- 1- Amniocentesis (15-17 weeks)
- 2- Chorionic villous sampling (9-10 wks)

B- DNA analysis:

- i- Southern blot
- ii- Restriction enzymes
- iii- PCR- RFLP
- iv- PCR amplification of DNA